NCI recognizes 12 outstanding clinical investigators with a two-year award to acknowledge and support leaders in clinical cancer research programs at NCI Designated Cancer Centers. This fourth cohort of investigators joins a group of 34 other outstanding clinical investigators who received this prestigious award in 2009, 2010, and 2011.
The 2011 and 2012 Awardees were recently recognized at a meeting held November 29, 2012, and at the 18th meeting of the NCI Clinical Trials and Translational Research Advisory Committee (CTAC) held on November 30, 2012.
An updated request for applications from NCI Designated Cancer Centers is anticipated in early 2013.
The goal of the NCTN is to develop and conduct state-of-the-art cancer treatment and advanced imaging clinical trials, especially large, definitive multi-institutional trials evaluating new cancer therapies and related clinical approaches for both adult and pediatric patients. Comprehensive discussions with all major clinical trial stakeholders and NCI Advisory Boards over a 2-year period led to the development of the new Network structure described in the Funding Opportunity Announcements (FOAs). The NCTN consists of 6 components, each with its own FOA. These components are: Network Group Operations Centers; Network Group Statistics and Data Management Centers; Network Group Integrated Translation Science Support Centers; Lead Academic Participating Site Centers; Network Radiotherapy and Imaging Core Services Centers; and a Canadian Collaborating Clinical Trials Network.
Available to funded Cooperative Groups (CGs) and Community Clinical Oncology Program (CCOP) Research Bases to support essential biomarker, imaging, and quality of life studies associated with clinical trial concepts. Additional eligibility is for phase 3 studies with an embedded Cost-Effectiveness Analysis (CEA) study. This is an "open competition" announcement with no specific receipt date.
The 22 Clinical Trials Working Group (CTWG) initiatives can be broadly categorized as addressing coordination, scientific prioritization, standardization, operational efficiency, and enterprise-wide concerns.
A central element of NCI's efforts to transform the clinical trials enterprise is the organization of Scientific Steering Committees composed of outside cancer experts and NCI senior investigators.